Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction - PubMed (original) (raw)
Gene transfer into humans--immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction
S A Rosenberg et al. N Engl J Med. 1990.
Free article
Abstract
Background and methods: Treatment with tumor-infiltrating lymphocytes (TIL) plus interleukin-2 can mediate the regression of metastatic melanoma in approximately half of patients. To optimize this treatment approach and define the in vivo distribution and survival of TIL, we used retroviral-mediated gene transduction to introduce the gene coding for resistance to neomycin into human TIL before their infusion into patients--thus using the new gene as a marker for the infused cells.
Results: Five patients received the gene-modified TIL. All the patients tolerated the treatment well, and no side effects due to the gene transduction were noted. The presence and expression of the neomycin-resistance gene were demonstrated in TIL from all the patients with Southern blot analysis and enzymatic assay for the neomycin phosphotransferase coded by the bacterial gene. Cells from four of the five patients grew successfully in high concentrations of G418, a neomycin analogue otherwise toxic to eukaryotic cells. With polymerase-chain-reaction analysis, gene-modified cells were consistently found in the circulation of all five patients for three weeks and for as long as two months in two patients. Cells were recovered from tumor deposits as much as 64 days after cell administration. The procedure was safe according to all criteria, including the absence of infections virus in TIL and in the patients.
Conclusions: These studies demonstrate the feasibility and safety of using retroviral gene transduction for human gene therapy and have implications for the design of TIL with improved antitumor potency, as well as for the possible use of lymphocytes for the gene therapy of other diseases.
Comment in
- Gene transfer into humans: a first step.
Cournoyer D, Caskey CT. Cournoyer D, et al. N Engl J Med. 1990 Aug 30;323(9):601-3. doi: 10.1056/NEJM199008303230909. N Engl J Med. 1990. PMID: 2381445 No abstract available.
Similar articles
- Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin.
Merrouche Y, Negrier S, Bain C, Combaret V, Mercatello A, Coronel B, Moskovtchenko JF, Tolstoshev P, Moen R, Philip T, et al. Merrouche Y, et al. J Clin Oncol. 1995 Feb;13(2):410-8. doi: 10.1200/JCO.1995.13.2.410. J Clin Oncol. 1995. PMID: 7844602 Clinical Trial. - Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Besser MJ, et al. Clin Cancer Res. 2010 May 1;16(9):2646-55. doi: 10.1158/1078-0432.CCR-10-0041. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406835 Clinical Trial. - Genetically marking human cells--results of the first clinical gene transfer studies.
Cai Q, Rubin JT, Lotze MT. Cai Q, et al. Cancer Gene Ther. 1995 Jun;2(2):125-36. Cancer Gene Ther. 1995. PMID: 7621260 Review. - The genetic modification of T cells for cancer therapy: an overview of laboratory and clinical trials.
Hwu P, Rosenberg SA. Hwu P, et al. Cancer Detect Prev. 1994;18(1):43-50. Cancer Detect Prev. 1994. PMID: 8162605 Review.
Cited by
- Current status of ex vivo gene therapy for hematological disorders: a review of clinical trials in Japan around the world.
Tani K. Tani K. Int J Hematol. 2016 Jul;104(1):42-72. doi: 10.1007/s12185-016-2030-2. Epub 2016 Jun 11. Int J Hematol. 2016. PMID: 27289360 Review. - Cell Therapy With TILs: Training and Taming T Cells to Fight Cancer.
Kumar A, Watkins R, Vilgelm AE. Kumar A, et al. Front Immunol. 2021 Jun 1;12:690499. doi: 10.3389/fimmu.2021.690499. eCollection 2021. Front Immunol. 2021. PMID: 34140957 Free PMC article. Review. - Chemical castration of melanoma patients does not increase the frequency of tumor-specific CD4 and CD8 T cells after peptide vaccination.
Vence LM, Wang C, Pappu H, Anson RE, Patel TA, Miller P, Bassett R, Lizee G, Overwijk WW, Komanduri K, Benjamin C, Alvarado G, Patel SP, Kim K, Papadopoulos NE, Bedikian AY, Homsi J, Hwu WJ, Boyd R, Radvanyi L, Hwu P. Vence LM, et al. J Immunother. 2013 May;36(4):276-86. doi: 10.1097/CJI.0b013e31829419f3. J Immunother. 2013. PMID: 23603862 Free PMC article. Clinical Trial. - Current issues in cancer. Biological therapy.
Perren T, Selby P. Perren T, et al. BMJ. 1992 Jun 20;304(6842):1621-3. doi: 10.1136/bmj.304.6842.1621. BMJ. 1992. PMID: 1378335 Free PMC article. Review. No abstract available. - Cytokines and cancer.
Malik S, Waxman J. Malik S, et al. BMJ. 1992 Aug 1;305(6848):265-7. doi: 10.1136/bmj.305.6848.265. BMJ. 1992. PMID: 1382767 Free PMC article. No abstract available.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical